Listening to what newborn cries reveal about infant health
Zoundream uses artificial intelligence and acoustic analysis to turn newborn cries into health insights and early disorder detection.

Newborn infants communicate entirely through crying, leaving parents and paediatricians to interpret what each distinct sound might mean. In 2018, Roberto Iannone, Ana Laguna Pradas, and Paolo Ingraito founded Zoundream in Basel to address this universal challenge in infant care. The health-tech team set out to build non-invasive acoustic technology capable of monitoring infant well-being directly at home. Beyond identifying daily needs such as hunger, discomfort, or fatigue, the founders recognised that baby cries contained untapped biological data. They set out to build software that could transform everyday acoustic signals into actionable health insights for families and clinical specialists alike.
At the core of the technology is the Acoustic Multi-Stage Interpreter, a deep learning system designed to analyse infant vocalisations. The software automatically detects infant cries while filtering out ambient household noise and background sounds. Zoundream integrates its sound recognition software into third-party hardware through major partnerships with brands including Philips Avent, Maxi-Cosi, and Motorola Nursery. By embedding artificial intelligence into standard baby monitors, the startup provides parents with continuous feedback during the early months of parenting without requiring extra equipment in the nursery.
The underlying research goes far beyond basic translation of everyday baby needs. In collaboration with research medical institutions such as Hospital Clinic Barcelona, University Medical Center Utrecht, and University Children's Hospital Zurich, Zoundream investigates complex physiological signals. Their scientific studies analyse acoustic data alongside electroencephalography signals, regional cerebral oxygen saturation, and facial expressions. This comprehensive approach helps researchers understand how specific acoustic patterns in newborn crying might correlate with underlying physical or neurodevelopmental conditions.
These clinical studies focus on using acoustic analysis for the early detection of neurodevelopmental disorders and pathologies. By studying large datasets of infant cries, the team aims to identify early indicators of conditions such as autism, specific language impairments, hearing disorders, hyperactivity, and sudden infant death syndrome. Spotting subtle acoustic markers early allows paediatricians to initiate preventive care and intervention far sooner than conventional diagnostic methods permit. This shift toward preventive infant healthcare forms the central mission driving the company's clinical development.
To accelerate its commercial expansion and technological development, Zoundream raised 4.69 million dollars in funding from CRB Health Tech and acquired Babbly in 2024. The venture has grown to a team of twenty-three employees, maintaining high user satisfaction metrics among parents who use the software. Roberto Iannone, who serves as chief executive officer alongside co-founders Ana Laguna Pradas and Paolo Ingraito, continues to build global partnerships with hardware manufacturers and healthcare research networks.
As Zoundream prepares to present its technology and clinical vision at Slush 2026, the company is focused on scaling its platform into homes worldwide. The software offers families peace of mind while providing paediatric teams with structured objective data during critical developmental stages. By converting sound into clear biological information, Zoundream is creating a new framework for non-invasive infant healthcare.
Find out more at zoundream.com
The Future FrontBe on the cover.Twice a month we put the people shaping what's next on our cover.Apply for the cover





